


Annual Review of Propoxyphene Products



Oklahoma Health Care Authority
September 2008

Current Prior Authorization Requirements

Approval Criteria for Darvocet A500 and Balacet 325

- Documented need to restrict acetaminophen use
- Concurrent use of acetaminophen-containing products
- Documented renal insufficiency or hepatic impairment
- A quantity limit of 180/30 on each of the products also applies.


Trends in Utilization of Propoxyphene products

Fiscal Year	Total Members	Total Claims	Total Cost	Cost per Claim	Per-Diem Cost	Total Units	Total Days
2007	17,820	33,087	\$239,618.26	\$7.24	\$0.73	1,373,780	329,214
2008	16,975	31,547	\$214,117.32	\$6.79	\$0.63	1,352,466	338,521
Percent Change	-4.7%	-4.7%	-10.6%	-6.2%	-13.7%	-1.6%	2.8%
	-845	-1,540	(\$25,500.94)	(\$0.45)	(\$0.10)	-21,314	9,307


Utilization of Propoxyphene Products in FY 08

Medication	Claims	Members	Units	Days	Cost	Units/Day	Claims/Member	Per-diem
Propoxyphene-N w/ APAP tab 100-650 mg	31,209	16,801	1,342,390	336,030	\$208,550.36	3.99	1.86	\$0.62
Propoxyphene-N w/ APAP tab 50-325 mg	338	265	10,076	2,491	\$5,566.96	4.04	1.28	\$2.23
Darvocet A500	0	0	0	0	0	0	0	0
Balacet 325	0	0	0	0	0	0	0	0
Totals	31,547	16,975	1,352,466	338,521	\$214,117.32	4.00	1.86	\$0.63

Demographics of Members Utilizing Propoxyphene Products in FY 2008



Prescribers of Propoxyphene Products in FY 08



Recommendations

The College of Pharmacy has no recommendations for this category at this time.